This company has been marked as potentially delisted and may not be actively trading. Stellar Biotechnologies (SBOT) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock SBOT vs. NATR, TSVT, INZY, AARD, FHTX, AMRN, LFCR, ZYBT, ESPR, and BOLTShould you be buying Stellar Biotechnologies stock or one of its competitors? The main competitors of Stellar Biotechnologies include Nature's Sunshine Products (NATR), 2seventy bio (TSVT), Inozyme Pharma (INZY), Aardvark Therapeutics (AARD), Foghorn Therapeutics (FHTX), Amarin (AMRN), Lifecore Biomedical (LFCR), Zhengye Biotechnology (ZYBT), Esperion Therapeutics (ESPR), and Bolt Biotherapeutics (BOLT). These companies are all part of the "medical" sector. Stellar Biotechnologies vs. Its Competitors Nature's Sunshine Products 2seventy bio Inozyme Pharma Aardvark Therapeutics Foghorn Therapeutics Amarin Lifecore Biomedical Zhengye Biotechnology Esperion Therapeutics Bolt Biotherapeutics Nature's Sunshine Products (NASDAQ:NATR) and Stellar Biotechnologies (NASDAQ:SBOT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, community ranking, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk. Do analysts prefer NATR or SBOT? Nature's Sunshine Products presently has a consensus price target of $18.33, suggesting a potential upside of 27.14%. Given Nature's Sunshine Products' stronger consensus rating and higher possible upside, equities analysts plainly believe Nature's Sunshine Products is more favorable than Stellar Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nature's Sunshine Products 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Stellar Biotechnologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has better earnings and valuation, NATR or SBOT? Nature's Sunshine Products has higher revenue and earnings than Stellar Biotechnologies. Stellar Biotechnologies is trading at a lower price-to-earnings ratio than Nature's Sunshine Products, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNature's Sunshine Products$456.62M0.58$15.08M$0.5327.21Stellar Biotechnologies$210K276.91-$5.03M-$1.76-6.20 Is NATR or SBOT more profitable? Nature's Sunshine Products has a net margin of 3.81% compared to Stellar Biotechnologies' net margin of -1,782.64%. Nature's Sunshine Products' return on equity of 11.08% beat Stellar Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Nature's Sunshine Products3.81% 11.08% 7.23% Stellar Biotechnologies -1,782.64%-51.12%-48.37% Do insiders and institutionals have more ownership in NATR or SBOT? 79.4% of Nature's Sunshine Products shares are held by institutional investors. Comparatively, 1.7% of Stellar Biotechnologies shares are held by institutional investors. 4.7% of Nature's Sunshine Products shares are held by insiders. Comparatively, 7.8% of Stellar Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media favor NATR or SBOT? In the previous week, Nature's Sunshine Products had 4 more articles in the media than Stellar Biotechnologies. MarketBeat recorded 4 mentions for Nature's Sunshine Products and 0 mentions for Stellar Biotechnologies. Nature's Sunshine Products' average media sentiment score of 1.05 beat Stellar Biotechnologies' score of 0.00 indicating that Nature's Sunshine Products is being referred to more favorably in the media. Company Overall Sentiment Nature's Sunshine Products Positive Stellar Biotechnologies Neutral Does the MarketBeat Community favor NATR or SBOT? Stellar Biotechnologies received 65 more outperform votes than Nature's Sunshine Products when rated by MarketBeat users. Likewise, 66.48% of users gave Stellar Biotechnologies an outperform vote while only 64.02% of users gave Nature's Sunshine Products an outperform vote. CompanyUnderperformOutperformNature's Sunshine ProductsOutperform Votes16964.02% Underperform Votes9535.98% Stellar BiotechnologiesOutperform Votes23466.48% Underperform Votes11833.52% SummaryNature's Sunshine Products beats Stellar Biotechnologies on 13 of the 17 factors compared between the two stocks. Get Stellar Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for SBOT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SBOT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SBOT vs. The Competition Export to ExcelMetricStellar BiotechnologiesPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$58.15M$6.88B$5.57B$8.51BDividend YieldN/A2.51%5.27%4.15%P/E Ratio-6.208.4626.7519.65Price / Sales276.91262.48404.17152.18Price / CashN/A65.8538.2534.64Price / Book5.156.526.964.59Net Income-$5.03M$143.26M$3.23B$248.23M Stellar Biotechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SBOTStellar BiotechnologiesN/A$10.91-8.3%N/A+382.7%$58.15M$210K-6.2025Gap DownHigh Trading VolumeNATRNature's Sunshine Products3.4919 of 5 stars$14.59+0.6%$18.33+25.7%-4.1%$267.74M$456.62M16.58850Positive NewsTSVT2seventy bioN/A$5.00flat$5.00N/A$266.15M$48.37M-2.69440INZYInozyme Pharma3.1678 of 5 stars$3.98-0.3%$11.75+195.2%-15.8%$256.96MN/A-2.5550AARDAardvark TherapeuticsN/A$11.68-1.1%$31.25+167.6%N/A$256.23MN/A0.0018News CoverageAnalyst DowngradeAnalyst RevisionGap DownFHTXFoghorn Therapeutics2.1517 of 5 stars$4.59+2.9%$12.13+164.2%-17.7%$255.85M$23.50M-2.39120Positive NewsAMRNAmarin0.4312 of 5 stars$12.33-3.1%$7.00-43.2%-14.9%$255.32M$214.11M-137.00360Gap DownLFCRLifecore Biomedical1.9158 of 5 stars$6.78-1.0%$8.00+18.0%+29.4%$251.03M$130.31M-12.11690News CoverageZYBTZhengye BiotechnologyN/A$5.16-12.7%N/AN/A$243.38M$189.75M0.00278Gap DownESPREsperion Therapeutics4.0446 of 5 stars$1.20-1.6%$6.25+420.8%-60.9%$237.84M$259.57M-1.88200News CoverageAnalyst RevisionBOLTBolt Biotherapeutics3.2133 of 5 stars$6.14-5.0%$2.50-59.3%-59.9%$235.41M$3.64M-3.5990News CoveragePositive NewsShort Interest ↓High Trading Volume Related Companies and Tools Related Companies NATR Competitors TSVT Competitors INZY Competitors AARD Competitors FHTX Competitors AMRN Competitors LFCR Competitors ZYBT Competitors ESPR Competitors BOLT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SBOT) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stellar Biotechnologies Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Stellar Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
